Cargando…

Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab

INTRODUCTION: We present a case of cystitis, which was considered to be an immune‐related adverse event associated with nivolumab administration. CASE PRESENTATION: A 47‐year‐old man suffered from sudden onset urinary symptoms after 18 cycles of nivolumab treatment for stage IV pulmonary adenocarcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yajima, Shugo, Nakanishi, Yasukazu, Matsumoto, Shunya, Tanabe, Kenji, Sugano, Masato, Masuda, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294138/
https://www.ncbi.nlm.nih.gov/pubmed/34308272
http://dx.doi.org/10.1002/iju5.12286
_version_ 1783725178020167680
author Yajima, Shugo
Nakanishi, Yasukazu
Matsumoto, Shunya
Tanabe, Kenji
Sugano, Masato
Masuda, Hitoshi
author_facet Yajima, Shugo
Nakanishi, Yasukazu
Matsumoto, Shunya
Tanabe, Kenji
Sugano, Masato
Masuda, Hitoshi
author_sort Yajima, Shugo
collection PubMed
description INTRODUCTION: We present a case of cystitis, which was considered to be an immune‐related adverse event associated with nivolumab administration. CASE PRESENTATION: A 47‐year‐old man suffered from sudden onset urinary symptoms after 18 cycles of nivolumab treatment for stage IV pulmonary adenocarcinoma. Urine culture and urine cytology were both negative. The symptoms were inferred to be related to nivolumab administration, and a bladder biopsy under spinal anesthesia was performed. The histopathological examination showed the evidence of allergic‐related cystitis. We planned to administer corticosteroids, but the urinary symptoms disappeared after the bladder biopsy. Nivolumab treatment was continued without recurrent bladder symptoms. CONCLUSION: We reported a case of cystitis after treatment with nivolumab, which served as a reminder to consider the possibility of immune‐related adverse events as a potential cause for any symptoms that develop during treatment with immuno‐oncology drugs.
format Online
Article
Text
id pubmed-8294138
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82941382021-07-23 Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab Yajima, Shugo Nakanishi, Yasukazu Matsumoto, Shunya Tanabe, Kenji Sugano, Masato Masuda, Hitoshi IJU Case Rep Case Reports INTRODUCTION: We present a case of cystitis, which was considered to be an immune‐related adverse event associated with nivolumab administration. CASE PRESENTATION: A 47‐year‐old man suffered from sudden onset urinary symptoms after 18 cycles of nivolumab treatment for stage IV pulmonary adenocarcinoma. Urine culture and urine cytology were both negative. The symptoms were inferred to be related to nivolumab administration, and a bladder biopsy under spinal anesthesia was performed. The histopathological examination showed the evidence of allergic‐related cystitis. We planned to administer corticosteroids, but the urinary symptoms disappeared after the bladder biopsy. Nivolumab treatment was continued without recurrent bladder symptoms. CONCLUSION: We reported a case of cystitis after treatment with nivolumab, which served as a reminder to consider the possibility of immune‐related adverse events as a potential cause for any symptoms that develop during treatment with immuno‐oncology drugs. John Wiley and Sons Inc. 2021-03-23 /pmc/articles/PMC8294138/ /pubmed/34308272 http://dx.doi.org/10.1002/iju5.12286 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Yajima, Shugo
Nakanishi, Yasukazu
Matsumoto, Shunya
Tanabe, Kenji
Sugano, Masato
Masuda, Hitoshi
Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab
title Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab
title_full Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab
title_fullStr Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab
title_full_unstemmed Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab
title_short Improvement of urinary symptoms after bladder biopsy: A case of pathologically proven allergy‐related cystitis during administration of nivolumab
title_sort improvement of urinary symptoms after bladder biopsy: a case of pathologically proven allergy‐related cystitis during administration of nivolumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294138/
https://www.ncbi.nlm.nih.gov/pubmed/34308272
http://dx.doi.org/10.1002/iju5.12286
work_keys_str_mv AT yajimashugo improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab
AT nakanishiyasukazu improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab
AT matsumotoshunya improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab
AT tanabekenji improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab
AT suganomasato improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab
AT masudahitoshi improvementofurinarysymptomsafterbladderbiopsyacaseofpathologicallyprovenallergyrelatedcystitisduringadministrationofnivolumab